Alnylam Pharmaceuticals (ALNY) is advancing in the cardiovascular therapy arena with its partnership with Roche to commence a late-stage trial for zilebesiran. Zilebesiran, an innovative therapy for heart disease, faced challenges during Phase 2 trials. While the 300 mg dose met primary objectives, a larger dose did not yield additional efficacy. The anticipation is high as the companies plan to begin the ZENITH trial by 2025, marking a significant step forward in therapeutic interventions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.